

# Letter to the editor: FIGO good practice recommendations on modifiable causes of iatrogenic preterm birth

We read with great interest the FIGO good practice recommendations on modifiable causes of iatrogenic preterm birth.<sup>1</sup> Avoiding iatrogenic prematurity should be one of the main goals of all obstetricians. The balance between maternal and fetal morbidity/mortality is sometimes difficult to establish; especially with regard to pregnancy-induced hypertension, a condition that carries a considerable risk for the mother. Our concern is especially true for low- and middle-income settings, where surveillance and early diagnosis of pre-eclampsia represent a great challenge.

In this paper, the authors state that patients with pregnancyinduced hypertension-i.e. gestational hypertension-should be offered delivery from 39 weeks onward. The paper uses as references HYPITAT I<sup>2</sup> and II<sup>3</sup> trials, and an individual patient meta-analysis by Bernardes et al.<sup>4</sup> However, the HYPITAT I trial concludes that induction of labor should be advised for women with mild hypertensive disease (gestational hypertension and mild pre-eclampsia) after 37 weeks of gestation, and the HYPITAT II trial studies patients before 37 weeks of gestation.<sup>2,3</sup> The conclusion of the Bernardes et al. meta-analysis states that the risk of neonatal distress respiratory syndrome is reduced when induction of labor is implemented at or after 36 weeks of gestation.<sup>4</sup>

Following these important studies, several associations worldwide updated their recommendations, suggesting induction of labor for patients with pre-eclampsia or gestational hypertension at or after 37 weeks of gestation.<sup>5-9</sup>

In light of this evidence, we would like to kindly ask the authors for some clarification about the reasons for such a recommendation.

Mario Dias Correa Junior<sup>1</sup> Jose Carlos Peraçoli<sup>2</sup> Sérgio Hofmeister Martins Costa<sup>3</sup> Maria Laura Costa do Nascimento<sup>4</sup> Henri Augusto Korkes<sup>5</sup> for RBHEG - Rede Brasileira de Estudos de Hipertensão na Gravidez\*

<sup>1</sup>Department of Gynecology and Obstetrics, Federal University of Minas Gerais, Belo Horizonte, Brazil

Linked article: This correspondence comments on the Special Article from Valencia et al.: https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/ijgo.13857

© 2022 International Federation of Gynecology and Obstetrics.

<sup>2</sup>Department of Gynecology and Obstetrics, Botucatu Medical School, São Paulo State University, UNESP, Botucatu, São Paulo, Brazil

<sup>3</sup>Department of Obstetrics and Gynecology, School of Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

<sup>4</sup>Department of Obstetrics and Gynecology, University of Campinas, Campinas, Brazil

<sup>5</sup>Department of Obstetrics, Catholic Medical School, São Paulo, Brazil

#### Correspondence

Mario Dias Correa Junior, Department of Gynecology and Obstetrics, Federal University of Minas Gerais, Av Alfredo Balena, 190, sala 217, Belo Horizonte, MG, Brazil. Email: correajr@gmail.com

#### REFERENCES

- 1. Valencia CM, Mol BW, Jacobson B. FIGO working Group for Preterm Birth. FIGO good practice recommendations on modifiable causes of iatrogenic preterm birth. Int J Gynecol Obstet. 2021;155(1):8-12.
- 2. Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36weeks' gestation (HYPITAT): a multicenter, open-label randomized controlled trial. Lancet. 2009;374(9694):979-988.
- 3. Broekhuijsen K, van Baaren GJ, van Pampus MG, et al. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomized controlled trial. Lancet. 2015:385(9986):2492-2501.
- 4. Bernardes TP, Zwertbroek EF, Broekhuijsen K, et al. Delivery or expectant management for prevention of adverse maternal and neonatal outcomes in hypertensive disorders of pregnancy: an individual participant data meta-analysis. Ultrasound Obstet Gynecol. 2019;53(4):443-453.
- 5. American College of Obstetricians and Gynecologists' committee on obstetric practice, Society for Maternal-Fetal Medicine. Medically indicated late-preterm and early-term deliveries: ACOG Committee opinion, number 831. Obstet Gynecol. 2021;138(1):e35-e39.
- Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018;13:291-310.
- 7. NICE Guideline. Hypertension in pregnancy: diagnosis and management. Published: 25 June 2019. www.nice.org.uk/guidance/ng133

<sup>\*</sup>Other members of RBHEG - Rede Brasileira de Estudos de Hipertensão na Gravidez are listed at the Appendix section.

\_\_\_\_\_

- WILEY GYVECOLOGY OBSTETRICS
- 8. Magee LA, Pels A, Helewa M, Rey E, Peter von Dadelszen, SOGC hypertension Guideline Committee. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014;36(5):416-438.
- 9. Peraçoli JC, Borges VTM, Ramos JGL, et al. Pre-eclampsia/ Eclampsia. *Rev Bras Ginecol Obstet*. 2019;41(5):e1-e2.

### APPENDIX A

334

## OTHER MEMBERS OF RBHEG – REDE BRASILEIRA DE ESTUDOS DE HIPERTENSÃO NA GRAVIDEZ

Alberto Moreno Zaconeta; Ana Cristina P. F. Araujo; Carlos Henrique Esteves Freire; Edilberto Alves Pereira da Rocha Filho; Edson Vieira da Cunha Filho; Francisco Lázaro Pereira de Sousa; José Geraldo Lopes Ramos; Leandro Gustavo de Oliveira; Maria Rita de Souza Mesquita; Nelson Sass; Ricardo de Carvalho Cavalli; Carlos Eduardo Poli de Figueiredo.